312 completed, 87 terminated, 82 recruiting, 77 active not recruiting. 682 Phase 2, 174 Phase 1, 13 Phase 3.
Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-11-18 |
| Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 25 | 2027-01-01 | 2026-11-03 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 55 | 2026-12-01 | 2026-09-10 |
| Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 29 | 2026-12-01 | 2026-11-16 |
| Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma Lenalidomide, Bruton's tyrosine kinase inhibitor, Chidamide - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 87 | 2026-11-01 | 2026-11-04 |
| CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-10-15 | 2026-10-26 |
| F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma F182112 Plus Isatuximab and Lenalidomide - Multiple Myeloma (MM), Transplant-eligible Patients | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-10-01 | 2026-09-18 |
| Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL Zanubrutinib, Lenalidomide - Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib | Phase 2 | Recruiting | Xiaohui Ren | 33 | 2026-09-25 | 2026-11-10 |
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-09-15 | 2026-09-18 |
| A Open-Label Phase in Participants With Multiple Myeloma Dexamethasone, IBI3003, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 120 | 2026-08-15 | 2026-08-14 |
| Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC Lenalidomide, Targeted Therapy, Immune Checkpoint Inhibitors - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Shunda Du | 32 | 2026-08-12 | 2026-09-21 |
| ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide - Multiple Myeloma, Newly Diagnosed Multiple Myeloma | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 160 | 2026-08-01 | 2026-06-23 |
| Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Daratumumab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma, Multiple Myeloma | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2026-07-01 | 2026-06-09 | |
| AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL Polatuzumab Vedotin, Rituximab (R), Zanubrutinib - Large B-Cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 112 | 2026-06-30 | 2026-07-21 |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2026-06-05 | 2026-06-18 | |
| QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms QLS4131, QL2109, Pomalidomide - Malignant Plasma Cell Neoplasms | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 162 | 2026-06-01 | 2026-05-01 |
| AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL Polatuzumab Vedotin, rituximab, Cyclophosphamide - Large B-Cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 178 | 2026-05-06 | 2026-05-19 |
Showing 20 of 682. Sign in to see all of them.
Multiple Myeloma (253) · Lymphoma, Large B-Cell, Diffuse (71) · Leukemia, Lymphocytic, Chronic, B-Cell (58) · Recurrence (50) · Lymphoma, Follicular (46) · Lymphoma (43) · Lymphoma, Mantle-Cell (37) · Neoplasms, Plasma Cell (37) · Myelodysplastic Syndromes (32) · Lymphoma, Non-Hodgkin (29) · Lymphoma, B-Cell, Marginal Zone (27) · Leukemia (23) · Leukemia, Myeloid, Acute (18) · Lymphoma, B-Cell (17) · Waldenstrom Macroglobulinemia (12)
M.D. Anderson Cancer Center (45) · National Cancer Institute (NCI) (26) · Celgene (23) · Mayo Clinic (21) · Memorial Sloan Kettering Cancer Center (19) · Celgene Corporation (16) · Ruijin Hospital (13) · H. Lee Moffitt Cancer Center and Research Institute (12) · The First Affiliated Hospital with Nanjing Medical University (11) · Dana-Farber Cancer Institute (10) · Weill Medical College of Cornell University (10) · Institute of Hematology & Blood Diseases Hospital, China (9) · Arbeitsgemeinschaft medikamentoese Tumortherapie (7) · Peking Union Medical College Hospital (7) · University Health Network, Toronto (7)
United States (386) · China (85) · France (64) · Germany (47) · Italy (46) · Spain (44) · Canada (32) · United Kingdom (32) · Sweden (20) · Australia (19) · Austria (19) · Denmark (19) · South Korea (18) · Belgium (16) · Greece (16)
Hani Hassoun, MD (4) · Ravi Vij, M.D. (4) · Robert Knight, MD (4) · Shaji K. Kumar, MD (4) · Bruno Carneiro de Medeiros (3) · Craig B. Reeder, MD (3) · Evangelos Terpos, Prof (3) · Felicitas Hitz, MD (3) · Liren Qian, PhD (3)
PMID 29358183, PMID 33357481, PMID 39319495, PMID 23834234, PMID 35285981, PMID 35549810, PMID 26181891, PMID 27531679, PMID 32325490, PMID 34182226, PMID 34826409, PMID 35132679, PMID 35952327, PMID 38649340, PMID 38652812, PMID 17021321, PMID 17893227, PMID 17989313, PMID 18161005, PMID 18334676, PMID 18606983, PMID 18824593, PMID 18987358, PMID 19118065, PMID 19182205, PMID 19705057, PMID 19720904, PMID 20385792, PMID 20508619, PMID 20651074, PMID 20724537, PMID 21051557, PMID 21228334, PMID 21495023, PMID 21504290, PMID 21551228, PMID 21596852, PMID 21630308, PMID 21719884, PMID 21725050, PMID 21812019, PMID 21937701, PMID 22033493, PMID 22058200, PMID 22241792, PMID 22354206, PMID 22422823, PMID 22495176, PMID 22504925, PMID 22517904
2023 (15), P30CA015083 (14), 2009 (10), 2008 (6), 2015 (6), U10CA180821 (5), 2019 (4), 2025 (4), P30CA014599 (4), P30CA015704 (4), U10CA031946 (4), U10CA032102 (4), U10CA180888 (4), 2017 (3), P30CA016672 (3)